Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Harvard Bioscience (HBIO) Share-based Compensation (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Share-based Compensation for 16 consecutive years, with $459000.0 as the latest value for Q4 2025.

Quarterly Share-based Compensation fell 52.24% to $459000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, down 49.02% year-over-year, with the annual reading at $1.9 million for FY2025, 57.26% down from the prior year.
Share-based Compensation for Q4 2025 was $459000.0 at Harvard Bioscience, up from $18000.0 in the prior quarter.
The five-year high for Share-based Compensation was $1.4 million in Q4 2023, with the low at $18000.0 in Q3 2025.
Average Share-based Compensation over 5 years is $753500.0, with a median of $1.0 million recorded in 2021.
The sharpest move saw Share-based Compensation soared 51.37% in 2021, then crashed 92.33% in 2023.
Over 5 years, Share-based Compensation stood at $1.0 million in 2021, then fell by 2.23% to $1.0 million in 2022, then skyrocketed by 36.83% to $1.4 million in 2023, then tumbled by 30.46% to $961000.0 in 2024, then tumbled by 52.24% to $459000.0 in 2025.
According to Business Quant data, Share-based Compensation over the past three periods came in at $459000.0, $18000.0, and $95000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.